Literature DB >> 26300023

Symptom Interference Severity and Health-Related Quality of Life in Pulmonary Arterial Hypertension.

Lea Ann Matura1, Annette McDonough2, Diane L Carroll3.   

Abstract

CONTEXT: While assessing symptom severity is an important component of evaluating symptoms, understanding those symptoms that interfere with patients' lives is also key. Pulmonary arterial hypertension (PAH) is a chronic disease resulting in right heart failure and increased mortality. Patients with PAH experience multiple symptoms but we do not know which symptoms and to what extent their symptoms interfere with daily life.
OBJECTIVES: To: (1) describe the prevalence of those symptoms that interfere with life; (2) describe the severity of symptom interference; and (3) determine those sociodemographic and clinical characteristics and interfering symptoms associated with health-related quality of life (HRQOL) in patients with PAH.
METHODS: A convenience sample of 191 patients with PAH completed a sociodemographic form, the Pulmonary Arterial Hypertension Symptom Interference Scale (PAHSIS) and the Medical Outcomes Survey Short Form-36 to measure HRQOL. Hierarchical multiple linear regression was used to analyze demographic and medical characteristics along with symptom interference from the PAHSIS as predictors of HRQOL from the composite mental and physical health summary scores of the Short Form-36.
RESULTS: The most interfering symptoms reported were fatigue, shortness of breath with exertion, and difficulty sleeping. Age, gender, functional class, oxygen use, fatigue, dizziness, and Raynaud phenomenon were associated with the HRQOL physical health summary scores. The symptoms fatigue and SOB while lying down were associated with the HRQOL mental health summary scores.
CONCLUSION: Patients with PAH are experiencing multiple symptoms that are interfering with their HRQOL and ability to function.
Copyright © 2016 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Symptoms; interference; pulmonary arterial hypertension; quality of life

Mesh:

Year:  2015        PMID: 26300023      PMCID: PMC4698220          DOI: 10.1016/j.jpainsymman.2015.07.012

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  44 in total

1.  The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): a measure of health-related quality of life and quality of life for patients with pulmonary hypertension.

Authors:  S P McKenna; N Doughty; D M Meads; L C Doward; J Pepke-Zaba
Journal:  Qual Life Res       Date:  2006-02       Impact factor: 4.147

2.  The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.

Authors:  J E Ware; C D Sherbourne
Journal:  Med Care       Date:  1992-06       Impact factor: 2.983

3.  Health-related quality of life in patients with pulmonary arterial hypertension.

Authors:  Shirin Shafazand; Mary K Goldstein; Ramona L Doyle; Mark A Hlatky; Michael K Gould
Journal:  Chest       Date:  2004-11       Impact factor: 9.410

4.  Validating the SF-36 health survey questionnaire: new outcome measure for primary care.

Authors:  J E Brazier; R Harper; N M Jones; A O'Cathain; K J Thomas; T Usherwood; L Westlake
Journal:  BMJ       Date:  1992-07-18

5.  Dyspnea in relation to symptoms of anxiety and depression: A prospective population study.

Authors:  Asa Neuman; María Gunnbjörnsdottir; Alf Tunsäter; Lennarth Nyström; Karl A Franklin; Eva Norrman; Christer Janson
Journal:  Respir Med       Date:  2006-03-03       Impact factor: 3.415

6.  Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon.

Authors:  Peter A Merkel; Karen Herlyn; Richard W Martin; Jennifer J Anderson; Maureen D Mayes; Patrice Bell; Joseph H Korn; Robert W Simms; Mary Ellen Csuka; Thomas A Medsger; Naomi F Rothfield; Michael H Ellman; David H Collier; Arthur Weinstein; Daniel E Furst; Sergio A Jiménez; Barbara White; James R Seibold; Fredrick M Wigley
Journal:  Arthritis Rheum       Date:  2002-09

7.  The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue.

Authors:  E M Smets; B Garssen; B Bonke; J C De Haes
Journal:  J Psychosom Res       Date:  1995-04       Impact factor: 3.006

8.  Prevalence and screening of dyspnea interfering with daily life activities in ambulatory patients with advanced lung cancer.

Authors:  Keiko Tanaka; Tatsuo Akechi; Toru Okuyama; Yutaka Nishiwaki; Yosuke Uchitomi
Journal:  J Pain Symptom Manage       Date:  2002-06       Impact factor: 3.612

9.  Cognitive, emotional, and quality of life outcomes in patients with pulmonary arterial hypertension.

Authors:  Joanne White; Ramona O Hopkins; Eric W Glissmeyer; Natalie Kitterman; C Gregory Elliott
Journal:  Respir Res       Date:  2006-03-31

10.  Prospective study of physical activity and physical function in early old age.

Authors:  Melvyn M Hillsdon; Eric J Brunner; Jack M Guralnik; Michael G Marmot
Journal:  Am J Prev Med       Date:  2005-04       Impact factor: 5.043

View more
  7 in total

1.  Symptoms among emerging adults with inflammatory bowel disease: a descriptive study.

Authors:  Kendra Kamp; Sharon Dudley-Brown; Margaret Heitkemper; Gwen Wyatt; Barbara Given
Journal:  Res Nurs Health       Date:  2019-10-10       Impact factor: 2.228

2.  A wrinkle in time: circadian biology in pulmonary vascular health and disease.

Authors:  Andrew J Bryant; Elnaz Ebrahimi; Amy Nguyen; Christopher A Wolff; Michelle L Gumz; Andrew C Liu; Karyn A Esser
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2021-12-01       Impact factor: 5.464

Review 3.  Systematic Review of Health-Related Quality of Life in Patients with Pulmonary Arterial Hypertension.

Authors:  Shuyan Gu; Huimei Hu; Hengjin Dong
Journal:  Pharmacoeconomics       Date:  2016-08       Impact factor: 4.981

4.  Symptom severity and its effect on health-related quality of life over time in patients with pulmonary hypertension: a multisite longitudinal cohort study.

Authors:  Janelle Yorke; Christi Deaton; Malcolm Campbell; Linda McGowen; Paul Sephton; David G Kiely; Iain Armstrong
Journal:  BMJ Open Respir Res       Date:  2018-03-01

5.  Multidimensional fatigue in pulmonary hypertension: prevalence, severity and predictors.

Authors:  Todd M Tartavoulle; Aryn C Karpinski; Andrew Aubin; Benzi M Kluger; Oliver Distler; Lesley Ann Saketkoo
Journal:  ERJ Open Res       Date:  2018-03-23

6.  Implantable system for treprostinil: a real-world patient experience study.

Authors:  Shelley Shapiro; Robert C Bourge; Patti Pozella; David F Harris; Erick H Borg; Andrew C Nelsen
Journal:  Pulm Circ       Date:  2020-04-22       Impact factor: 3.017

7.  Symptom phenotypes in pulmonary arterial hypertension: The PAH "symptome".

Authors:  Lea Ann Matura; Jamison D Fargo; Kathleen Boyle; Jason S Fritz; Kerri A Smith; Jeremy A Mazurek; Diane Pinder; Christine L Archer-Chicko; Harold I Palevsky; Allan I Pack; Marilyn S Sommers; Steven M Kawut
Journal:  Pulm Circ       Date:  2022-07-01       Impact factor: 2.886

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.